Skip to content
Their Record

House Roll Call 610, 104th Congress · August 4, 1995

(HOUSE REJECTED THE SANDERS AMENDMENT THAT SOUGHT TO PROHIBIT USE OF FUNDS BY THE NIH TO CONVEY EXCLUSIVE LICENSE OR PATENT RIGHTS FOR A DRUG; RELEASE ON AN EXCLUSIVE BASIS DRUG TESTING INFORMATION DERIVED FROM NIH ANIMAL TESTS OR HUMAN CLINICAL TRIALS; OR ENTER INTO A COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT UNDER THE STEVENSON-WYDLER TECHNOLOGY INNOVATION ACT OF 1980 AND PROVIDE THAT THESE RESTRICTIONS COULD BE WAIVED WHEN IT IS DETERMINED THAT A REASONABLE PRICING CLAUSE IS NOT IN THE PUBLIC INTEREST.)

Question before the chamber: On Agreeing to the Amendment

141 yea · 284 nayFailed9 not voting or present
Democrat135 yea · 56 nay
Republican5 yea · 228 nay
Independent1 yea · 0 nay

Solid = yea, faded = nay.

The measure

H.R. 2127 ↗

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 1996

Policy area: Economics and Public Finance — assigned by Library of Congress subject specialists, not by this site.

How this vote is scored

Which tracked issues this roll call counts toward, and which way a yea vote moves a member on each. Direction is decided per issue, because one bill can push two issues opposite ways.

  • Spending & BudgetDirection unreadable — not scored

    excluded:model-unclear (0.90) Restrictions on NIH drug patenting and licensing agreements concern regulatory policy, not general spending levels.

    Tagged by: policy-area:Economics and Public Finance

    Axis: Fiscal expansion ← → Fiscal restraint

Who voted which way

Every member recorded on this roll call, with the party they sat with at the time.

Yea (141)

Nay (284)

Not voting or present (9)

Vote records come from Voteview (voteview.com); bill titles and policy areas from the congress.gov API. See methodology for how the record was built.